



IBRANCE (palbociclib)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

Part A - Patient Patient Information

Patient Information)n				
First Name:			Last Name:		
Insurance Carrier N	lame/Number:				
Group Number:		Client ID:			
Date of Birth (YYYY/MM/DD):		Relationship: Employee Spouse Dependent			
Language: English French			Gender: Male Female		
Address:					
City:		Province:		Postal Code:	
Email address:					
Telephone (home):		Telephone (cell):		Telephone (work):	
Please check any box that applies to the patient: The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed. The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.					
Coordination of be	enefits				
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.				
Primary Coverage	Has the patient applied			Yes No N/A	





IBRANCE (palbociclib)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





IBRANCE (palbociclib)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

BRANCE (palbocicli	b)	New re	equest Rei	newal request*
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administrat	ion:			
Home Phys	ician's office/Private Cli	nic Private Clinic (within Hos	pital - no public or g	overnment funding)
Hospital (inpatient)	Hospital (outpa	tient)		
Name of the hospital or	private clinic:			
·	•			
Address:				
City:	Pro	vince:	Postal code:	
^ Please Submit proof	of prior coverage if avai	liable		
SECTION 2 - FLIGIR	II ITV CDITEDIA			
	ILITY CRITERIA he patient satisfies the b	pelow criteria:		
1. Please indicate if t	he patient satisfies the l	pelow criteria:		
1. Please indicate if t Breast Cancer – First-L For the treatm	he patient satisfies the bine ine ent of hormone receptor	pelow criteria: r (HR)-positive, human epidermal growns in the same of the sa		2 (HER2)-negative
1. Please indicate if t Breast Cancer – First-L For the treatm advanced or m	he patient satisfies the bine ent of hormone receptor netastatic breast cancer	r (HR)-positive, human epidermal grov	an adult, AND	2 (HER2)-negative
1. Please indicate if t Breast Cancer – First-L For the treatmadvanced or m The patient is a	he patient satisfies the bine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me	r (HR)-positive, human epidermal grovas initial endocrine based therapy in	an adult, AND sal woman, AND	2 (HER2)-negative
1. Please indicate if t Breast Cancer - First-L For the treatm advanced or m The patient is a limit of the patient has	he patient satisfies the kine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me s not received prior syste	r (HR)-positive, human epidermal grovas initial endocrine based therapy in nopausal woman, or a postmenopaus	an adult, AND sal woman, AND	2 (HER2)-negative
1. Please indicate if t Breast Cancer - First-L For the treatm advanced or m The patient is a limit of the patient has	he patient satisfies the kine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me s not received prior syste	r (HR)-positive, human epidermal grow as initial endocrine based therapy in nopausal woman, or a postmenopaus emic therapy in the metastatic settin	an adult, AND sal woman, AND	2 (HER2)-negative
1. Please indicate if t Breast Cancer - First-L For the treatm advanced or m The patient is a limit of the patient has	he patient satisfies the bine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me is not received prior systeme used in combination we	r (HR)-positive, human epidermal grow as initial endocrine based therapy in nopausal woman, or a postmenopaus emic therapy in the metastatic settin	an adult, AND sal woman, AND	2 (HER2)-negative
1. Please indicate if t Breast Cancer - First-L For the treatmadvanced or m The patient is a The patient ha BRANCE will b Breast Cancer - Secon	he patient satisfies the bine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me is not received prior system used in combination with the deline	r (HR)-positive, human epidermal growns initial endocrine based therapy in nopausal woman, or a postmenopausemic therapy in the metastatic setting with an aromatase inhibitor	an adult, AND sal woman, AND g, AND	
1. Please indicate if t Breast Cancer - First-L For the treatm advanced or m The patient is a library in the patient ha library is library in the patient ha library in the patient ha library is library in the patient ha library in the patient ha library is library in the patient had libr	he patient satisfies the bine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me is not received prior system used in combination with the deline ent of hormone receptor	r (HR)-positive, human epidermal growns initial endocrine based therapy in nopausal woman, or a postmenopausemic therapy in the metastatic setting with an aromatase inhibitor r (HR)-positive, human epidermal growns and adult, AND	an adult, AND sal woman, AND g, AND	
1. Please indicate if t Breast Cancer - First-L For the treatm advanced or m The patient is a library libra	he patient satisfies the kine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me s not received prior system be used in combination volume d-Line ent of hormone receptor netastatic breast cancer a man or a postmenopar	r (HR)-positive, human epidermal growns initial endocrine based therapy in nopausal woman, or a postmenopausemic therapy in the metastatic setting with an aromatase inhibitor r (HR)-positive, human epidermal growns and adult, AND	an adult, AND sal woman, AND g, AND wth factor receptor 2	2 (HER2)-negative
Breast Cancer - First-L For the treatment advanced or more advanced or mo	he patient satisfies the bine ent of hormone receptor netastatic breast cancer a man, a pre- or peri-me is not received prior system as the used in combination with the used in the use	r (HR)-positive, human epidermal growns initial endocrine based therapy in nopausal woman, or a postmenopausemic therapy in the metastatic setting with an aromatase inhibitor reference (HR)-positive, human epidermal growns an adult, AND usal woman, OR	an adult, AND sal woman, AND g, AND wth factor receptor 2 th a luteinizing horm	2 (HER2)-negative





IBRANCE (palbociclib)

OR	
None of the above criteria applies.	
Relevant additional information:	
SECTION 3 - PRESCRIBER INFORMATION	
Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





IBRANCE (palbociclib)

SECTION 5 - CONTACT US

<u> </u>	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please	se 'prio	r auth'	as th
Ш	reference number.			

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 2010 STN Waterloo Waterloo, ON N2J 0A6